Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma

NCT07000617 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT07000617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07000617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 2
Overall status
Recruiting
Start date
March 21, 2025
Completion date
December 31, 2028
Enrollment
57 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

nk/t cell lymphoma